Results 251 to 260 of about 447,577 (315)

10-Year Change in the Laboratory-Based Prevalence of Chronic Kidney Disease in Patients from a Brazilian Cardiologic Center. [PDF]

Epidemiologia (Basel)
Samaan F, Silveira RC, Franchini KG, Feres F, Mastroianni-Kirsztajn G, Sesso R.   +5 more
europepmc   +1 more source

Analyse molekularpathologischer Faktoren des EGFR-Signalwegs und ihre Bedeutung als prädiktive Faktoren in der Behandlung des metastasierten kolorektalen Karzinoms mit dem EGFR-Antikörper Cetuximab [PDF]

, 2013
Kapaun, Christine
core  

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

A review of epidermal growth factor receptor ligands in glucose homeostasis. [PDF]

Front Endocrinol (Lausanne)
Chan KY, Deng CJ, Chen X, Cai Y, Jia S, Wong CM.   +5 more
europepmc   +1 more source

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad, Anshu Arora, Arun Arora, Jeena Vaid, Arif Khan   +4 more
wiley   +1 more source

Active surveillance of drug safety in healthcare data: Sequential monitoring of bacterial and serious urinary tract infection risk in sodium‐glucose cotransporter 2 inhibitor users

British Journal of Clinical Pharmacology, EarlyView.
Abstract Introduction Active surveillance of adverse events using healthcare data is emerging as complementary to the monitoring of spontaneous reports and stand‐alone pharmacoepidemiologic studies. The risk of urinary tract infections (UTIs) was listed as a special warning for sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) when marketed in Europe
Haoxin Le, Dilsad Simay Peker, Lukas Frederic Westphal, Nikolai Brun, Christine Erikstrup Hallgreen, Morten Andersen   +5 more
wiley   +1 more source

Panitumumab labeled with Auger electron-emitting ^197gHg/^197mHg: cytotoxicity on human breast cancer cells and tumour and normal tissue uptake in mice with EGFR-overexpressing breast cancer xenografts. [PDF]

EJNMMI Radiopharm Chem
Chu ACK, Ho F, Chan C, Cai Z, Ganga-Sah Y, Randhawa P, Ramogida CF, Radchenko V, Reilly RM.   +8 more
europepmc   +1 more source

Metabolomic investigation of cisplatin‐induced acute kidney injury in paediatric cancer patients

British Journal of Clinical Pharmacology, EarlyView.
Aim Cisplatin causes acute kidney injury (AKI) in approximately 46% of paediatric cancer patients who receive it. Serum creatinine (SCr) is a poor biomarker of cisplatin nephrotoxicity, because there is a delay between cisplatin infusion and SCr elevation.
Yong Jin Lim, Amy Thachil, Kelly McMahon, Ross T. Tsuyuki, S. Rod Rassekh, Lesley G. Mitchell, Prasad Devarajan, Cherry Mammen, Bruce C. Carleton, Geoffrey D. E. Cuvelier, Victor A. Lewis, Colin J. D. Ross, Alexandra P. Zorzi, Sylvain Baruchel, Raveena Ramphal, Eric Bouffet, Mathieu Lemaire, Tom D. Blydt‐Hansen, Brad L. Urquhart, The Applying Biomarkers to Minimize Long‐Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Research Study Group, Tom Blydt‐Hansen, Bruce C. Carleton, Geoff D. E. Cuvelier, Sunil Desai, Prasad Devarajan, Conrad Fernandez, Adam Fleming, Paul Gibson, Caroline Laverdiere, Victor Lewis, Mary L. McBride, Bruno Michon, Shahrad Rod Rassekh, Colin J. D. Ross, Christine Sabapathy, Kirk R. Schultz, Michael Zappitelli, Alexandra Zorzi   +37 more
wiley   +1 more source

External validation of the BAN‐ADHF diuretic‐resistance score in the DAPA‐RESIST clinical trial

British Journal of Clinical Pharmacology, EarlyView.
Diuretic resistance in worsening heart failure (HF) is associated with poorer outcomes and, although common, can be challenging to identify. The recently developed BAN‐ADHF score can potentially identify patients with worsening HF at risk of diuretic resistance.
Dominic M. Alfonso, Kieran F. Docherty, Matthew M. Y. Lee, Patrick B. Mark, Alex McConnachie, Joanna Osmanska, Bethany Stanley, Atefeh Talebi, Mark C. Petrie, John J. V. McMurray, Ross T. Campbell   +10 more
wiley   +1 more source